Showing results (41-50 of 102) with videos related to

Sort By:
Pageof 11
Immunity|April 23, 2005
Gene modification strategies to induce tumor immunityAmanda Murphy, Jennifer A Westwood, Michele W L Teng, et al.
Oncoimmunology|May 10, 2019
Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcomeJing Liu, Jake S O'Donnell, Juming Yan, et al.
Cancer Research|February 5, 2011
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasisJohn Stagg, Upulie Divisekera, Helene Duret, et al.
Cancer Research|July 3, 2014
Antimetastatic effects of blocking PD-1 and the adenosine A2A receptorDeepak Mittal, Arabella Young, Kimberley Stannard, et al.
Oncoimmunology|June 7, 2018
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancerElizabeth Ahern, Heidi Harjunpää, Jake S O'Donnell, et al.
Oncoimmunology|May 10, 2019
The role of NK cells and CD39 in the immunological control of tumor metastasesHaiyan Zhang, Dipti Vijayan, Xian-Yang Li, et al.
The Journal of Biological Chemistry|September 20, 2005
T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent mannerMichele W L Teng, Michael H Kershaw, Yoshihiro Hayakawa, et al.
Cancer Research|August 8, 2012
Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium stateMichele W L Teng, Matthew D Vesely, Helene Duret, et al.
Stroke|November 20, 2010
Ipsilateral stroke in a patient with horizontal gaze palsy with progressive scoliosis and a subcortical infarctAdeline S L Ng, Yih-Yian Sitoh, Yi Zhao, et al.
Oncoimmunology|June 5, 2013
TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancerKaori Sakuishi, Shin Foong Ngiow, Jenna M Sullivan, et al.
Pageof 11